newsfilter
← Earnings
Earnings Releases·

MoonLake Immunotherapeutics — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $79.5 million for Q3 2026, widening from $61.8 million in Q2 2026, driven by a 37% increase in R&D expenses to $68.9 million due to accrued milestone license fees for the BLA submission.
  • Submitted the BLA for sonelokimab in hidradenitis suppurativa on September 30, 2026, with FDA acceptance notification expected by late November 2026 and a planned U.S. commercial launch in the second half of 2027.
  • Maintains a strong liquidity position with $498.5 million in cash and equivalents, sufficient to fund operations through mid-2028, alongside up to $400 million in remaining non-dilutive funds via the Hercules Capital debt facility.
  • Advanced clinical pipeline includes positive Week 16 Phase 3 IZAR-1 results in psoriatic arthritis, completed enrollment for the Phase 3 IZAR-2 trial, and upcoming data releases for the VELA-TEEN, P-OLARIS, and NOVA trials scheduled between late 2026 and early 2027.
Company
MOONLAKE IMMUNOTHERAPEUTICS
Sector
Healthcare
Industry
Biotechnology